- Home
- KGS vs IBRX Comparison
KGS vs IBRX Comparison
Compare KGS & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KGS | IBRX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 7.2B |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KGS | IBRX |
|---|---|---|
| Price | $64.92 | $7.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $57.17 | $12.57 |
| AVG Volume (30 Days) | 1.7M | ★ 12.2M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 58.93 | 38.71 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,308,100,000.00 | $113,288,000.00 |
| Revenue This Year | $12.30 | $88.59 |
| Revenue Next Year | $7.96 | $131.15 |
| P/E Ratio | $330.00 | ★ N/A |
| Revenue Growth | 12.83 | ★ 668.31 |
| 52 Week Low | $30.06 | $1.95 |
| 52 Week High | $77.68 | $12.43 |
Technical Indicators
Market Signals| Indicator | KGS | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 45.06 |
| Support Level | $55.10 | $6.69 |
| Resistance Level | $77.13 | $8.54 |
| Average True Range (ATR) | 2.99 | 0.57 |
| MACD | -0.58 | -0.15 |
| Stochastic Oscillator | 11.50 | 17.74 |
Price Performance
Historical ComparisonAbout KGS Kodiak Gas Services Inc.
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. The company manages its business through two operating segments: Contract Services and Other Services. Contract Services consists of operating company-owned and customer-owned compression, gas treating, and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings. Maximum revenue for the company is generated from its Contract Services segment.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.